GIFT Nifty 🇮🇳: (+81, 25926)
The Good News for Bullish Nifty Traders: Investors shall welcome a softer-than-expected US inflation report that strengthens expectations for Fed rate cuts.
As per the CME Group FedWatch, futures traders are currently pricing in a 97% chance the central bank will lower the federal funds rate by a quarter-percentage point this Wednesday, October 29th .
Odds of another rate cut in December have risen to 92% from 73% one month ago.
The Other 2-Positive Catalyst:
1) Possible trade-deal between the US and China.
2) Renewed optimism on trade, as hopes rise that the U.S. may cut tariffs on Indian imports to 15–16%.
Technically, all bullish eyes set on Nifty’s all-time peak at 26,277.35, which is likely to be sooner rather than later.
For the day, Nifty bulls may aim to reclaim the 26000 mark.
The earnings calendar promises to be eventful. Key Earnings on radar this week:
• Monday (October 27): Indian Oil Corporation, Adani Energy Solutions, Indus Towers, and SRF.
• Tuesday (October 28): TVS Motor Company, Adani Green Energy, Tata Capital, and Shree Cements.
• Wednesday (October 29): Larsen & Toubro, Coal India, Hindustan Petroleum Corporation, and United Breweries.
STOCKS IN SPOTLIGHT
1) Federal Bank (+0.13%) gained after board approves capital raise proposal worth Rs 6,196.51 crore. The bank’s board approved a proposal to grant 27.29 crore warrants at a price of Rs 227 apiece to Asia II Topco XIII, amounting to a total cash consideration of Rs 6,196.51 crore.
2) Cipla tumbled 3.61% after the company announced that it has entered into an agreement with Eli Lilly to distribute tirzepatide in India under the brand name Yurpeak. The drug, indicated for the treatment of type 2 diabetes and obesity, will be priced at par with Eli Lilly’s Mounjaro.
3) Hindustan Unilever Ltd (HUL) plunged 3.33% after the firm posted a 4% year-on-year rise in consolidated net profit for Q2 FY26 to Rs 2,694 crore, but aided by a one-off tax gain.
4) Kotak Bank Q2 results: Net profit falls 2.7% YoY, NII up 4% at Rs 7,311 crore. Net Advances increased 16% YoY to Rs 462,688 crore as at September 30, 2025 from Rs 399,522 crore as at September 30, 2024.
Now, before we get into detail of today’s trading session, here is the preferred trade on Nifty and Bank Nifty:
Nifty (25795): Buy at CMP. Stop at 25401. Targets 26000/26277. Aggressive targets at 26700-27000 zone.
Bank Nifty (57700): Buy at CMP. Stop at 56470. Targets 58350/58750. Aggressive targets at 59100-59500 zone.
Our chart of the day is bullish on BEL, SUN PHARMA, LAURUS LAB, and BLUE STAR on any early excessive intraday weakness with an interweek/Intermonth perspective.
The 1 Stock to Buy Right Now: Buy LAURUS LAB (CMP 926): Buy at CMP. Stop at 887. Targets 945/971. Aggressive targets at 1003. (Interweek Strategy). Rationale: Laurus reported a strong Q2 FY26 performance, with consolidated net profit soaring multifold to ₹194.97 crore, compared with ₹19.78 crore in Q2 FY25. Key interweek support 871. Major hurdles only at 945 mark. 200-DMA at 706.
Disclaimer/ Disclosure: The investments & trading ideas recommended in the market analysis, research reports, etc. may not be suitable for all investors. This article or data points does not construe investment advice as stock market investments are subject to market risks so please refer to your financial consultant advice before Investing or trading. All information is a point of view, and is for educational, Learning and informational use only. The author or the group admin accepts no liability for any interpretation of articles or comments on this platform being used for actual investments. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investors must make their own investment decisions based on their specific investment objectives, goals and financial position only after consulting with registered market intermediaries.